Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11285207 Bispecific antibodies specifically binding to PD1 and LAG3

Overview Structured Data Issues Contributors Activity

Is a

Patent

Date Filed

April 3, 2018

Date of Patent

March 29, 2022

Patent Application Number

15944394

Patent Citations

‌

US Patent 10344089 Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

‌

US Patent 10392445 Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

‌

US Patent 10562903 Bridged piperidine derivatives

‌

US Patent 10718762 Cellular based fret assay for the determination of simultaneous binding

‌

US Patent 10596173 Combination therapy of an HBV capsid assembly inhibitor and an interferon

‌

US Patent 10934352 Bi-specific antibodies against Tim-3 and PD-1 for immunotherapy in chronic immune conditions

‌

US Patent 10761097 Method for the detection of a binding partner of a multispecific binder

‌

US Patent 10287352 Bispecific antibodies specific for PD1 and TIM3

Patent Citations Received

‌

US Patent 11608376 Tumor-targeted agonistic CD28 antigen binding molecules

‌

US Patent 12023368 Immunoconjugates

‌

US Patent 12060435 Multi-specific ligand binders

‌

US Patent 12065478 HER2-targeting antigen binding molecules comprising 4-1BBL

Patent Inventor Names

Sabine Imhof-Jung

Stefan Seeber

Jens Fischer

Laura Codarri Deak

Patrick Alexander Aaron Weber

Christian Klein

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11285207

Patent Primary Examiner

CPC Code

Find more entities like US Patent 11285207 Bispecific antibodies specifically binding to PD1 and LAG3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API